These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37026591)

  • 21. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
    Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
    Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
    Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
    Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.
    Pasqualucci L; Migliazza A; Basso K; Houldsworth J; Chaganti RS; Dalla-Favera R
    Blood; 2003 Apr; 101(8):2914-23. PubMed ID: 12515714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
    Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
    Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
    Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
    J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type.
    El Jamal SM; Grada Z; El Dinali MH; Zhou H; Hassan SY; Saad AG; Gibson B; Zhou X; Abulsayen HA; Khadra HS; Friedman J; Shalaby H; Kadi A; Megahed M; Emberesh M; Teruya-Feldstein J; Firpo-Betancourt A; Haikel Y; Fraig M; Hassan M
    Lab Invest; 2019 Apr; 99(4):539-550. PubMed ID: 30446717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
    Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
    Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.
    Amengual JE; Clark-Garvey S; Kalac M; Scotto L; Marchi E; Neylon E; Johannet P; Wei Y; Zain J; O'Connor OA
    Blood; 2013 Sep; 122(12):2104-13. PubMed ID: 23913470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas.
    Ding BB; Yu JJ; Yu RY; Mendez LM; Shaknovich R; Zhang Y; Cattoretti G; Ye BH
    Blood; 2008 Feb; 111(3):1515-23. PubMed ID: 17951530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice.
    Pearce AC; Bamford MJ; Barber R; Bridges A; Convery MA; Demetriou C; Evans S; Gobbetti T; Hirst DJ; Holmes DS; Hutchinson JP; Jayne S; Lezina L; McCabe MT; Messenger C; Morley J; Musso MC; Scott-Stevens P; Manso AS; Schofield J; Slocombe T; Somers D; Walker AL; Wyce A; Zhang XP; Wagner SD
    J Biol Chem; 2021 Aug; 297(2):100928. PubMed ID: 34274316
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Tourneret A; Alame M; Rigau V; Bauchet L; Fabbro M; De Oliveira L; Cacheux V; Costes V; Lacheretz-Szablewski V
    J Clin Pathol; 2021 Oct; 74(10):650-656. PubMed ID: 32912960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
    Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
    Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms: comparison with lymphomas associated with BCL2 rearrangement.
    Muramatsu M; Akasaka T; Kadowaki N; Ohno H; Yamabe H; Edamura S; Dor S; Mori T; Okuma M; Fukuhara S
    Br J Haematol; 1996 Jun; 93(4):911-20. PubMed ID: 8703825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of primary central nervous system large B-cell lymphoma in the era of high-grade B-cell lymphoma: Detection of two cases with MYC and BCL6 rearrangements in a cohort of 12 cases.
    Pina-Oviedo S; Bellamy WT; Gokden M
    Ann Diagn Pathol; 2020 Oct; 48():151610. PubMed ID: 32889391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.
    Mamai A; Chau AM; Wilson BJ; Watson ID; Joseph BB; Subramanian PR; Morshed MM; Morin JA; Prakesch MA; Lu T; Connolly P; Kuntz DA; Pomroy NC; Poda G; Nguyen K; Marcellus R; Strathdee G; Theriault B; Subramaniam R; Mohammed M; Abibi A; Chan M; Winston J; Kiyota T; Undzys E; Aman A; Austin N; Du Jardin M; Packman K; Phillippar U; Attar R; Edwards J; O'Meara J; Uehling DE; Al-Awar R; Privé GG; Isaac MB
    ACS Med Chem Lett; 2023 Feb; 14(2):199-210. PubMed ID: 36793435
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model.
    Sandhu SK; Volinia S; Costinean S; Galasso M; Neinast R; Santhanam R; Parthun MR; Perrotti D; Marcucci G; Garzon R; Croce CM
    Proc Natl Acad Sci U S A; 2012 Dec; 109(49):20047-52. PubMed ID: 23169640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas.
    Perez-Rosado A; Artiga M; Vargiu P; Sanchez-Aguilera A; Alvarez-Barrientos A; Piris M
    J Pathol; 2008 Mar; 214(4):498-507. PubMed ID: 18189332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases.
    Al-Kawaaz M; Mathew S; Liu Y; Gomez ML; Chaviano F; Knowles DM; Orazi A; Tam W
    Am J Clin Pathol; 2015 Feb; 143(2):288-99. PubMed ID: 25596256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.